Therapeutic Plasma Exchange Market Size, Share, Forecast Report 2026 to 2035
Global Therapeutic Plasma Exchange Market Segmentation:
Global Therapeutic Plasma Exchange Market by Product & Technology,
- Product
- Consumables
- Devices
- Technology
- Centrifugation
- Membrane Separation
Global Therapeutic Plasma Exchange Market By Indication,
- Neurological Disorders: Guillain–Barré syndrome, Chronic inflammatory demyelinating polyneuropathy, Myasthenia gravis, Multiple sclerosis and PANDASa
- Hematology Disorders: Thrombotic, thrombocytopenic purpura, Atypical haemolytic uraemic syndrome, Hyperviscosity syndromes and Severe/symptomatic cryoglobulinaemia
- Renal Disorders: Goodpasture’s syndrome, Wegener’s glomerulonephritis and Antibody-mediated renal transplant rejection
- Metabolic Disorders: Familial hypercholesterolaemia (homozygous)
- Other Indications
Global Therapeutic Plasma Exchange Market By End Users,
- Blood Collection Centres & Blood Component Providers
- Hospitals & Transfusion Centres
- Other End Users
Global Therapeutic Plasma Exchange Market By Region,
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Therapeutic Plasma Exchange Market Snapshot
Chapter 4. Global Therapeutic Plasma Exchange Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Products & Technology Advancement in Ambulatory Mammography
Chapter 5. Market Segmentation 1: Products & Technology Estimates & Trend Analysis
5.1. Products & Technology & Market Share, 2025 & 2035
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2022 to 2035 for the following Products & Technology:
5.2.1. Product
Consumables
Devices
5.2.2. Technology
Centrifugation
Membrane Separation
Chapter 6. Market Segmentation 1: Indications & Trend Analysis
6.1. Indications & Market Share, 2025 & 2035
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2022 to 2035 for the following Indications:
6.2.1. Neurological Disorders
Guillain–Barré syndrome
Chronic inflammatory demyelinating polyneuropathy
Myasthenia gravis
Multiple sclerosis
PANDASa
6.2.2. Hematology Disorders
Thrombotic thrombocytopenic purpura
Atypical haemolytic uraemic syndrome
Hyperviscosity syndromes
Severe/symptomatic cryoglobulinaemia
6.2.3. Renal Disorders
Goodpasture’s syndrome
Wegener’s glomerulonephritis
Antibody-mediated renal transplant rejection
6.2.4. Metabolic Disorders
Familial hypercholesterolaemia (homozygous)
6.2.5. Other Indications
Chapter 7. Market Segmentation 1: End-Users & Trend Analysis
7.1. End-Users & Market Share, 2025 & 2035
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2022 to 2035 for the following End-Users
7.2.1. Blood Collection Centres & Blood Component Providers
7.2.2. Hospitals & Transfusion Centres
7.2.3. Other End Users
Chapter 8. Therapeutic Plasma Exchange Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts Products & Technology, 2022 - 2035
8.1.2. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2022 - 2035
8.1.3. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2022 - 2035
8.1.4. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2035
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2022 - 2035
8.2.2. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2022 - 2035
8.2.3. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2022 - 2035
8.2.4. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2022 - 2035
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2022 - 2035
8.3.2. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2022 - 2035
8.3.3. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2022 - 2035
8.3.4. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2022 - 2035
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2022 - 2035
8.4.2. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2022 - 2035
8.4.3. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2022 - 2035
8.4.4. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2022 - 2035
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts Products & Technology, 2022 - 2035
8.5.2. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2022 - 2035
8.5.3. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2022 - 2035
8.5.4. MEA revenue Therapeutic Plasma Exchange Market revenue (US$ Million) by country, (US$ Million) 2022 - 2035
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. TERUMO BCT, INC.
9.2.2. FRESENIUS SE & CO. KGAA
9.2.3. HAEMONETICS CORPORATION
9.2.4. BAXTER INTERNATIONAL INC.
9.2.5. ASAHI KASEI MEDICAL CO. LTD.
9.2.6. BRAUN MELSUNGEN AG
9.2.7. CERUS CORPORATION
9.2.8. KANEKA CORPORATION
9.2.9. KAWASUMI LABORATORIES, INC.
9.2.10. NIKKISO CO., LTD.
9.2.11. MILTENYI BIOTEC
9.2.12. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Terumo BCT, Inc., Fresenius SE & Co. KGaA, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Baxter International Inc.
Therapeutic plasma exchange market is segmented on the basis of product & technologies, end-users, and region. Based on the base of product and technology, the market is divided into the product (consumables & devices) and technology (centrifugation & membrane separation).
North American region is leading the Therapeutic Plasma Exchange Market.
Therapeutic Plasma Exchange Market Size is valued at USD 1.30 Bn in 2025 and is predicted to reach USD 2.65 Bn by the year 2035
Therapeutic Plasma Exchange Marke expected to grow at a 7.5% CAGR during the forecast period for 2026-2035.